Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

191.50SEK
16 Nov 2018
Change (% chg)

6.30kr (+3.40%)
Prev Close
185.20kr
Open
185.20kr
Day's High
192.55kr
Day's Low
185.20kr
Volume
1,088,906
Avg. Vol
963,707
52-wk High
299.60kr
52-wk Low
107.40kr

Summary

Name Age Since Current Position

Hakan Bjorklund

62 2016 Independent Chairman of the Board

Guido Oelkers

53 2017 President, Chief Executive Officer

Henrik Stenqvist

51 2018 Chief Financial Officer

Armin Reininger

61 2017 Head of Medical and Scientific Affairs

Milan Zdravkovic

48 2016 Head of Research & Development, Chief Medical Officer

Torbjorn Hallberg

49 2018 General Counsel and Head of Legal Affairs

Fredrik Wetterlundh

52 2018 Head of Human Resources

Hege Hellstrom

53 2017 Head of EMENAR

Rami Levin

49 2017 Head of North America

Norbert Oppitz

51 2017 Head of Specialty Care

Philip Wood

50 2017 Head of Haemophilia

David Allsop

55 2018 Director

Pia Axelsson

56 2017 Director, Employee Representative

Lennart Johansson

63 2010 Director

Bo-Gunnar Rosenbrand

55 2006 Director, Employee Representative

Helena Saxon

48 2011 Director

Elisabeth Svanberg

57 2018 Director

Annette Clancy

64 2014 Independent Director

Matthew Gantz

53 2012 Independent Director

Hans Schikan

60 2011 Independent Director

Jorgen Winroth

2012 Head of Investor Relations

Biographies

Name Description

Hakan Bjorklund

Dr. Hakan Bjorklund, Ph.D. has been Independent Chairman of the Board at Swedish Orphan Biovitrum AB (publ) since May 24, 2016. He is Chairman of Compensation & Benefits Committee and Member of the Nomination Committee. He has an extensive international background in the life science industry, from both R&D and sales and marketing. He has experience of leading healthcare companies in expansive development phases. He has been CEO, Nycomed; Member of the Board of Directors, Alere, Coloplast, Danisco, and Lundbeck and Board Member, Biovitrum 2001- 2007. He is Industry Executive at Avista Capital Partners and Chairman of the Board of Directors of Bonesupport AB. He holds Ph.D., Karolinska Institutet, Stockholm, Sweden.

Guido Oelkers

Dr. Guido Oelkers, Ph.D. has been appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB (publ), effective as of May 22, 2017. He holds PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London, Complementary studies in Economics, London School of Economics and Political Science. He is Board member of Sartorius AG. Previously, he was CEO, BSN Medical; Board member Meda; President & CEO, Gambro AB and held executive roles in Nycomed, Invida Holding and DKSH Group. He also held various country management positions in Aventis.

Henrik Stenqvist

Mr. Henrik Stenqvist has been appointed Chief Financial Officer at Swedish Orphan Biovitrum AB (publ) effective as of July 2018. Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joined Sobi from a position as CFO of Recipharm 2017-2018. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group (2003-2017), where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these. He was also CFO Pharmalink, 2001-2003, Regional Finance Director Astra Zeneca 1999-2000, Finance Director Astra Export&Trading, 1998-1999, Financial Manager, Astra Hungary, 1993-1997. Henrik Stenqvist holds a degree in Finance and Business Administration from the University of Linkoping, Sweden.

Armin Reininger

Mr. Armin Reininger, M.D., Ph.D. has been Head of Medical and Scientific Affairs at Swedish Orphan Biovitrum AB (publ) since January 1, 2017. Armin was previously Head of Medical Affairs EMEA Hemophilia, Baxter; Head of Global Medical Affairs Hematology, Baxalta; Head of Medical Affairs EMEA Hematology, Baxalta/Shire; Senior Physician University Clinic Munich; Harvard Medical School & Mass; General Hospital, Boston, MA; The Scripps Research Institute, La Jolla, CA. He was also Professor of Anatomy at the Ludwig Maximilians- University Munich, Germany. He holds M.D., Ph.D., Ludwig-Maximilians-University Munich, Germany; and is certified specialist in Transfusion Medicine.

Milan Zdravkovic

Mr. Milan Zdravkovic has been Head of Research & Development, Chief Medical Officer of Swedish Orphan Biovitrum AB (publ) since November 1, 2016. He joined Sobi from Novo Nordisk where he has had a 18-year tenure in the Research and Development organization responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity. He is DIA Advisory Council Europe, Middle East and Africa, Board member and co-founder of Selma Diagnostics Aps. He holds M.D., Ph.D. University of Aarhus, Denmark, M.Sc. Pharmaceutical Medicine, University of Surrey, United Kingdom.

Torbjorn Hallberg

Mr. Torbjorn Hallberg has been General Counsel and Head of Legal Affairs at Swedish Orphan Biovitrum AB (publ) since January 2018. He holds Master of Laws from University of Lund, Sweden. He previously was Vice President, General Counsel, Emerging Markets, Takeda Pharmaceuticals; Senior Director and Senior Corporate Counsel, Takeda Pharmaceuticals; Corporate Counsel, Nycomed Pharma; Corporate Counsel, Ferring Pharmaceuticals; Senior Associate/ Lawyer, Advokatfirman Lindahl.

Fredrik Wetterlundh

Mr. Fredrik Wetterlundh has been Head of Human Resources at Swedish Orphan Biovitrum AB (publ) since 2018. He holds a degree in HR Management from the University of Lund, Sweden. He previously was Global Human Resources Lead at Pfizer and held senior HR roles in Astra Zeneca, Kraft Foods as well as Codan Group.

Hege Hellstrom

Ms. Hege Hellstrom has been Head of EMENAR at Swedish Orphan Biovitrum AB (publ) since 2017. She has been employed since 2013. She holds BSc in Bioengineering, Oslo, Norway. She previously was Global Head Cardiovascular, Sanofi, Vice President Renal Europe and Head of Regional Liaisons, Sanofi; Vice President Renal and Endocrine Europe, Genzyme; General Manager Benelux, Genzyme. She spent 13 years in Baxter in different leadership roles.

Rami Levin

Mr. Rami Levin has been Head of North America at Swedish Orphan Biovitrum AB (publ) since 2017. He has been employed since 2014. He holds MBA from Rekanati Business School, Tel-Aviv University, Israel and BSc in Biology, Tel- Aviv University, Israel. He also serves on the Board of advisors of “Life Science Cares”, Corporate alliance member for Global Genes, Corporate council member for the National Organization for Rare Disorders (NORD), Regional chamber representative for the Swedish American Chamber of Commerce. Previously, he was Vice President of Marketing US, Managing Director Scandinavia, Global Marketing Head, Business Unit Manager, Merck. Product Manager, Schering AG.

Norbert Oppitz

Mr. Norbert Oppitz has been Head of Specialty Care at Swedish Orphan Biovitrum AB (publ) since 2017. He studied Business Administration, FH Rhenania Palatina/Mainz, Germany. He previously was Executive Committee member in charge of Latin America, BSN Medical; Executive Committee member Emerging Markets, Endo Pharmaceuticals; Head of Latin America, Takeda/ Nycomed; Country management roles at Roche Pharmaceuticals and Aventis Pharma.

Philip Wood

Mr. Philip Wood has served as Head of Haemophilia at Swedish Orphan Biovitrum AB (publ) since 2017. He has been employed since 2012. He holds BSc Joint Honors degree in Geology and Physical Geography, Charted Institute of Marketing certification, UK. He previously was Head of European Strategic Asset team, Hemophilia, and Business Unit Head Hemophilia, UK, Pfizer.

David Allsop

Mr. David Allsop has been Director of Swedish Orphan Biovitrum AB (publ) since May 9, 2018. He has a BSc Hons Chemistry from Coventry University, UK. He is Director and sole employee in U-R-NOT Ltd., through which Mr. Allsop offers advisory services to the pharma industry. He has more than 30 years’ of experience from research as well as marketing within the pharmaceuticals and health care industries. He also has international experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Until January 2018, he was Head of International in Amicus Therapeutics Ltd. Before then Mr. Allsop held a number of senior positions in Biogen 1998–2015.

Pia Axelsson

Ms. Pia Axelsson has been Director, Employee Representative at Swedish Orphan Biovitrum AB (publ) since May 4, 2017. She has been Deputy Board Member since 2009. She is representative of the council for negotiation and cooperation. She is Laboratory engineer.

Lennart Johansson

Mr. Lennart Johansson has been Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) (previously Biovitrum AB) since April 27, 2010. He also serves as Chairman of the Company's Audit Committee. Mr. Johansson is Member of the management team and Senior Advisor in Patricia Industries (division of Investor AB), Chairman of the Board of Fastighets AB Tinghuset 13, Board Member of Vectura Fastigheter AB, HI3G, Chalmers Ventures, Bonesupport AB and Deputy Board Member of Molnlycke Health Care. Formerly, he held the position of Chief Executive Officer at b-business partners and Emerging Technologies AB. He was also Board member of SAAB AB, IBX Group AB, Gambro Holding AB, Member of Investor AB management team. He holds a Master of Business Administration degree from Handelshogskolan i Stockholm.

Bo-Gunnar Rosenbrand

Mr. Bo-Gunnar Rosenbrand has been Employee Representative on the Board of Directors of Swedish Orphan Biovitrum AB (publ) (previously Biovitrum AB) since 2006. He was Deputy Member of the Board of the Company between 2001 and 2005. He is representative of the council for negotiation and cooperation. He is Laboratory Engineer.

Helena Saxon

Ms. Helena Saxon has served as Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since April 28, 2011. She also serves as Member of the Company's Audit Committee and Compensation & Benefits Committee. She holds a Master of Science degree from Handelshogskolan i Stockholm. She is also CFO at Investor AB and Board Member of SEB. Previously, she served as Chief Financial Officer of Hallvarsson & Halvarsson, Vice President of Investor AB and financial analyst at Goldman Sachs, as well as Board member of Aleris, Gambro and Molnlycke Health Care.

Elisabeth Svanberg

Ms. Elisabeth Svanberg has been Director of Swedish Orphan Biovitrum AB (publ) since May 9, 2018. She has MD and PhD from the University of Gothenburg, Sweden. Ms. Svanberg is associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016. She is member of the Board of Directors of Follicum AB and PledPharma AB, and has also previously served as board member of the Swedish American Chamber of Commerce New York. Previously she was Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016 and has worked with Bristol Myers Squibb (BMS) in the US leading the development of a novel diabetes medicine and subsequently served as Head of Medical Affairs for the Intercontinental region. 2000–2007, Ms. Svanberg worked at Serono International in the field of metabolism.

Annette Clancy

Ms. Annette V. Clancy has been Independent Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since May 8, 2014. She is Chairman of the Scientific Committee. Ms. Clancy has over 30 years of experience in the Pharmaceutical and Biotechnology Industry, working in a variety of roles in the United States and United Kingdom. She has Bachelor of Science Hons in Pharmacology from Bath University UK. She is Non-executive Chairman of the Board of Enyo SA and Lysogene SA. She is also Board Member of Obseva SA. She was previously Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).Since her retirement from GSK in 2008, Ms. Clancy has been appointed as Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-2013). She was also Chair of the Board of Genable Therapeutics and Senior Advisor, Biopharmaceutical Team of Frazier Helathcare.

Matthew Gantz

Mr. Matthew Gantz has served as Independent Member of the Board of Directors of Swedish Orphan Biovitrum AB (publ) since April 26, 2012. He is Member of the Board of Pennsylvania Life Sciences Association and Marine Corps Scholarship Foudnation. He also serves as CEO of OxThera AB. He was previously Executive Vice President in BTG Plc, an international healthcare company. Previously, he founded and served as Chief Executive Officer (CEO) of Acureon Pharmaceuticals. Is the past, he was also President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, he held a variety of United States sales and marketing roles at Abbott Laboratories Diagnostic Division. Mr. Gantz holds a Bachelor of Arts degree from Princeton University and a Master of Business Administration degree from Harvard Business School.

Hans Schikan

Mr. Hans GCP Schikan has served as Independent Member of the Board Directors of Swedish Orphan Biovitrum AB (publ) since April 28, 2011. He is also Member of the Company's Audit and Scientific Committees. He holds a Pharm.D degree from Universiteit Utrecht. He also serves as Chairman of the Board of Asceneuron, Interna and Complix, Board member of Hansa Medical, Therachon, Wilson Therapeutics and the Dutch Top Sector Life Sciences & Health and Advisor to various organizations in the Life Sciences & Health. Previously, he was CEO of Prosensa and member of Prosensa’s Supervisory Board, Board member of Top Institute Pharma, Chairman of Nefarma, the association for innovative medicines in the Netherlands, and a number of senior positions in the former Organon and Genzyme.

Jorgen Winroth

Mr. Jorgen Winroth has been appointed Head of Investor Relations at Swedish Orphan Biovitrum AB (publ), effective as of November 16, 2012. He has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. He has also served as Consultant providing strategic Investor Relations services to a number of Scandinavian companies including Hafslund Nycomed AS, AB SKF, Huhtamaki Oy. He also served as Vice President, Investor Relations at Pharmacia.